PPARG and breast cancer: The growth inhibitory effects of 1–4 μM γ-tocotrienol was significantly enhanced when given in combination with a subeffective dose (3.2 μM) of the PPARγ antagonist, GW9662, in MCF-7 breast cancer cells (Figure 3(a), Top).